Denali Therapeutics stock costs EUR 17.77 while analysts cite USD 35.85
Published on 10/05/2026 at 19:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Denali Therapeutics (ISIN US24823R1059) was trading at EUR 17.77 at Lang & Schwarz on October 5, 2026 at 7:30 p.m. CEST, unchanged versus the prior close of EUR 17.77, while MarketBeat reported on September 27, 2026 that analysts' average 12-month target was USD 35.85. The unchanged euro quote puts the immediate market signal on hold, while the target remains a separate US-dollar reference.
Q2 revenue starts the launch
The latest reported quarter shows why AVLAYAH commercialization is central to the valuation. According to MarketBeat, Denali reported USD 3.60 million of revenue in the second quarter of 2026 against USD 2.15 million of analyst consensus, while its loss was USD 0.68 per share versus an expected USD 0.51 loss.
Revenue therefore exceeded consensus by USD 1.45 million, but the per-share loss was USD 0.17 worse than expected. That combination gives the company a commercial proof point while keeping profitability firmly in the development-stage category.
Analyst target stays above the range
Denali's investor-relations site describes a biotechnology platform designed to move medicines across the blood-brain barrier and identifies AVLAYAH as approved in the United States. The company also lists Nasdaq Global Select Market trading under ticker DNLI, according to its Denali Therapeutics investor site.
The average analyst target of USD 35.85 stands 31.32 percent above the USD 27.30 52-week high, using the same US-dollar basis. The current market capitalization is USD 3.2 billion, while the 52-week range runs from USD 13.75 to USD 27.30, both as of October 5, 2026.
Euro quote stays unchanged
At Lang & Schwarz, Denali stock was trading at EUR 17.77 on October 5, 2026 at 7:30 p.m. CEST, unchanged versus the prior close of EUR 17.77 on October 2, 2026. The euro quote and the US-dollar analyst target are kept separate because they use different currencies.
Denali Therapeutics market snapshot
- Company: Denali Therapeutics Inc.
- ISIN: US24823R1059
- Ticker: DNLI
- Primary exchange: Nasdaq Global Select Market
- Price Lang & Schwarz (as of October 5, 2026, 7:30 p.m. CEST): EUR 17.77
- Change versus prior close: plus 0.00 percent
- Prior close Lang & Schwarz (October 2, 2026): EUR 17.77
- Market capitalization: USD 3.2 billion (as of October 5, 2026)
- 52-week range: USD 13.75-27.30 (as of October 5, 2026)
- Sector / Industry: Healthcare / Biotechnology
